Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
One of the first questions asked by newly diagnosed multiple myeloma patients is about a MM diet. “What foods should I add to my daily diet?” According to the research linked below, pomegranate juice (PGJ) is anti-angiogenic, PGJ kills MM and PGJ is integrative- it enhances the efficacy of Bortezomib aka Velcade.
The study linked and excerpted below is not saying that pomagranate juice (PGJ) is going to cure your MM. That would be silly. What the study below is saying is what dozens of studies have said about curcumin, resveratrol, green tea extract, omega-3 fatty acids and a host of anti-angiogenic foods have said.
Multiple myeloma is an incurable blood cancer. If a newly diagnosed MMer follows only conventional therapies such as revlimid, velcade and dexamethasone, he/she will endure several remissions and relapses, a host of short, long-term and late stage side effects such as rashes and nerve damage and eventually face MDR, multidrug resistence. Meaning that your MM no longer responds to conventional therapies.
Your choice is to hope for a series of longer than average remissions in addition to the invention of a cure or you can manage your MM for the rest of your life. This is the essense of the cure versus control debate.
The challenge newly diagnosed MMers face when thinking about the cure vs. control debate in MM, is that conventional oncology doesn’t consider anything beyond FDA approved therapies to be “evidence-based.” While your oncologist is probably okay with you exercising, eating healthier foods or even supplementing with basic nutrition, don’t expect him or her to propose integrative therapies such as PGJ, curcumin, or resveratrol to enhance the efficacy of revlimid. This is the definition of integrative therapies.
In my opinion the newly diagnosed MMer needs to utilize all of the evidenced-based therapies possible to manage his/her MM while managaging side effects for as long as possible. I drink and recommend PGJ. I supplement with a host of anti-MM supplements and I have been in complete remission from my MM since April of 1999.
To learn more about evidenced-based supplementation shown to kill MM, scroll down the page, post a question or comment and I will reply to you ASAP.
“Multiple myeloma (MM) is a clonal B-cell malignancy characterized by an accumulation of clonal plasma cells (PC) in the bone marrow (BM) leading to bone destruction and BM failure. Despite recent advances in pharmacological therapy, MM remains a largely incurable pathology. Therefore, novel effective and less toxic agents are urgently necessary. In the last few years, pomegranate has been studied for its potential therapeutic properties including treatment and prevention of cancer. Pomegranate juice (PGJ) contains a number of potential active compounds including organic acids, vitamins, sugars, and phenolic components that are all responsible of the pro-apoptotic effects observed in tumor cell line.
The aim of present investigation is to assess the antiproliferative and antiangiogenic potential of the PGJ in human multiple myeloma cell lines.
Our data demonstrate the anti-proliferative potential of PGJ in MM cells; its ability to induce G0/G1 cell cycle block and its anti-angiogenic effects. Interestingly, sequential combination of bortezomib/PGJ improved the cytotoxic effect of the proteosome inhibitor.
We investigated the effect of PGJ on angiogenesis and cell migration/invasion. Interestingly, we observed an inhibitory effect on the tube formation, microvessel outgrowth aorting ring and decreased cell migration and invasion as showed by wound-healing and transwell assays, respectively. Analysis of angiogenic genes expression in endothelial cells confirmed the anti-angiogenic properties of pomegranate. Therefore, PGJ administration could represent a good tool in order to identify novel therapeutic strategies for MM treatment, exploiting its anti-proliferative and anti-angiogenic effects.
Finally, the present research supports the evidence that PGJ could play a key role of a future therapeutic approach for treatment of MM in order to optimize the pharmacological effect of bortezomib, especially as adjuvant after treatment. View Full-Text